Skip to main content

Table 1 Baseline characteristics of children who completed six months of follow-up classified by allocated treatment

From: Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study

 

Artemether-lumefantrine (n = 87)

Artemisinin-naphthoquine (n = 89)

P -value

Age (months)

41.4 ± 16.6

44.0 ± 15.4

0.28

Male (%)

43 (49.4)

47 (52.8)

0.76

Falciparum malaria (%)*

80 (92.0)

73 (82.0)

0.07

Vivax malaria (%)*

10 (11.5)

21 (23.6)

0.04

Axillary temperature (°C)

38.3 ± 1.3

38.1 ± 1.4

0.51

Weight (kg)

12.4 ± 2.5

12.6 ± 2.5

0.50

Respiratory rate (/min)

31.1 ± 8.8

31.3 ± 10.1

0.97

Pulse rate (/min)

122.8 ± 20.8

122.5 ± 20.7

0.91

Mid upper arm circumference (cm)

14.5 ± 1.2

14.5 ± 1.2

0.97

Height (cm)

93.1 ± 10.6

93.0 ± 10.5

0.97

Body Mass Index (kg/m2)

14.4 ± 1.6

14.7 ± 2.1

0.38

Palpable spleen ≥2 cm (%)

35 (40.2)

38 (42.7)

0.76

Haemoglobin (g/L)

89.8 ± 17.1

94.0 ± 17.7

0.11

Blood glucose (mmol/L)

6.6 ± 1.8

6.7 ± 1.8

0.71

  1. Data are numbers (percentages) or mean ± SD.
  2. *8 patients (3 artemether-lumefantrine-treated and 5 artemisinin-naphthoquine-treated) had mixed P. falciparum/P. vivax infections.